KEEGAN WOOD: Open Payments
NPI 1417471459 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$744 in 33 payments from 8 companies in 2025. Trend: 2023 $1,649 · 2024 $1,388 · 2025 $744
Food & beverage: $744
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $190 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $160 |
| Vanda Pharmaceuticals Inc. | 3 | $110 |
| Alkermes, Inc. | 5 | $87 |
| Teva Pharmaceuticals USA, Inc. | 3 | $66 |
| Neurocrine BioSciences, Inc. | 2 | $55 |
| ABBVIE INC. | 2 | $46 |
| Janssen Pharmaceuticals, Inc | 2 | $29 |
Products named: CAPLYTA, REXULTI, FANAPT, ARISTADA, INGREZZA, ABILIFY ASIMTUFII, AUSTEDO XR, VRAYLAR.
Industry payments across CA — which companies pay providers there.
